Pages that link to "Q59379923"
Jump to navigation
Jump to search
The following pages link to F. Estelle R. Simons (Q59379923):
Displaying 50 items.
- Glucocorticoids for the treatment of anaphylaxis (Q24200443) (← links)
- Allergen-specific oral immunotherapy for peanut allergy (Q24200573) (← links)
- Adrenaline auto-injectors for the treatment of anaphylaxis with and without cardiovascular collapse in the community (Q24201463) (← links)
- Oral immunotherapy for peanut allergy (Q24234537) (← links)
- Adrenaline auto-injectors for the treatment of anaphylaxis with and without cardiovascular collapse in the community (Q24235431) (← links)
- Glucocorticoids for the treatment of anaphylaxis (Q24236588) (← links)
- Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock (Q24241174) (← links)
- Glucocorticoids for the treatment of anaphylaxis (Q24242546) (← links)
- H1-antihistamines for the treatment of anaphylaxis with and without shock (Q24246206) (← links)
- Zinc finger-like structure in U1-specific protein C is essential for specific binding to U1 snRNP (Q24312620) (← links)
- Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) (Q26740215) (← links)
- Systemic chemokine and chemokine receptor responses are divergent in allergic versus non-allergic humans (Q28212133) (← links)
- Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel (Q28300001) (← links)
- ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle (Q28355722) (← links)
- Immunologic mechanisms in mosquito allergy: correlation of skin reactions with specific IgE and IgG antibodies and lymphocyte proliferation response to mosquito antigens (Q29868680) (← links)
- Epinephrine and its use in anaphylaxis: current issues (Q30227116) (← links)
- Anaphylaxis: Recent advances in assessment and treatment (Q30227506) (← links)
- Anaphylaxis: evidence-based long-term risk reduction in the community (Q30229893) (← links)
- Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study (Q30417919) (← links)
- Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort (Q30424114) (← links)
- Adrenaline for the treatment of anaphylaxis: cochrane systematic review. (Q30857448) (← links)
- Fatal anaphylaxis registries data support changes in the who anaphylaxis mortality coding rules (Q31154653) (← links)
- The allergy archives: pioneers and milestones (Q33235365) (← links)
- Regulation of the high affinity IgE receptor (Fc epsilonRI) in human neutrophils: role of seasonal allergen exposure and Th-2 cytokines (Q33326647) (← links)
- Are plasma IL-10 levels a useful marker of human clinical tolerance in peanut allergy? (Q33612250) (← links)
- International consensus on (ICON) anaphylaxis (Q33687257) (← links)
- World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings (Q34116481) (← links)
- World allergy organization guidelines for the assessment and management of anaphylaxis (Q34319703) (← links)
- Advances in H1-antihistamines (Q34368803) (← links)
- World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base (Q34368942) (← links)
- H2-antihistamines for the treatment of anaphylaxis with and without shock: a systematic review (Q34400351) (← links)
- Elevated antigen-driven IL-9 responses are prominent in peanut allergic humans (Q34446837) (← links)
- 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines (Q34500152) (← links)
- H1-Antihistamines: more relevant than ever in the treatment of allergic disorders (Q34542391) (← links)
- Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report (Q34563621) (← links)
- Self-injectable epinephrine for first-aid management of anaphylaxis (Q34576686) (← links)
- Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis (Q34586645) (← links)
- World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) (Q34589248) (← links)
- Clinical pharmacology of H1-antihistamines (Q34734428) (← links)
- H1-antihistamines and the central nervous system. (Q34734468) (← links)
- H1-antihistamines in children (Q34734485) (← links)
- Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review (Q34980929) (← links)
- Comparative pharmacology of H1 antihistamines: clinical relevance (Q35041029) (← links)
- Insights and advances in chronic urticaria: a Canadian perspective (Q35108534) (← links)
- First do no harm: managing antihistamine impairment in patients with allergic rhinitis. (Q35126061) (← links)
- Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations (Q35212261) (← links)
- Mosquito allergy: immune mechanisms and recombinant salivary allergens (Q35667177) (← links)
- First-aid treatment of anaphylaxis to food: focus on epinephrine (Q35766809) (← links)
- Mosquito salivary allergen Aed a 3: cloning, comprehensive molecular analysis, and clinical evaluation (Q35853310) (← links)
- Clinical outcomes and adverse effect monitoring in allergic rhinitis (Q36061500) (← links)